Sarepta Therapeutics is no longer priced as a gene-therapy compounder. After a year of safety events, a boxed warning, and a label that now covers only ambulatory Duchenne patients, the Cambridge company is a cash-generating exon-skipping franchise carrying a damaged one-time gene therapy and a licensed RNA-silencing pipeline that has not yet earned a commercial multiple. Michael Severino took the chief executive role at the end of July, succeeding Doug Ingram after more than a decade that built the Duchenne franchise and then watched Elevidys collide with acute liver failure. The investment debate is whether the residual enterprise value above the phosphorodiamidate morpholino oligomer, or PMO, cash engine is a cheap option on a second franchise or leftover of a growth story that has already ended.
The June quarter shows the new shape of the profit and loss rather than a rebound. Net product sales landed at $328.7 million, almost unchanged from the prior quarter. The older PMO franchise held near $230.6 million. Elevidys contributed $98.1 million. That gene-therapy line is a fraction of the year-ago run-rate after the label lost non-ambulatory patients. Combined research and selling costs fell sharply after the mid-2025 restructuring. GAAP operations still printed a slim profit even after a $39.0 million patent contingency. Cash, restricted cash and investments rose to $945.0 million during the quarter. The franchise can fund itself. What it cannot yet do is re-rate as a growth company.
Management narrowed full-year net product guidance to the low end of the prior band and said the second half sits modestly below the first. Elevidys infusions lag enrollment by about six months. Recent start-form gains, if they persist, show up next year rather than in the next print. The load-bearing tests sit in the second half. Multiple-ascending-dose data arrive for the myotonic dystrophy and facioscapulohumeral programs. Whether Elevidys start forms keep improving under the new commercial push is the commercial test. The open question is whether the market still overpays for a pipeline that has not produced a second approved product, or whether it underpays a self-funded rare-disease cash engine.